The Human Microbiota and Its Relationship with Allergies by Fyhrquist, Nanna
The Human Microbiota and
Its Relationship with
AllergiesNanna Fyhrquist, PhDa,b,*KEYWORDS
 Allergic disease  Human microbiota  Dysbiosis  Biodiversity hypothesis
KEY POINTS
 Perturbations in the human microbiome may have profound effects on the host, which
may result in developing chronic inflammation and disease, especially in genetically pre-
disposed individuals.
 The mechanisms via which the human microbiota may be regulating the immune system,
either by providing protective signals or stimulating effector mechanisms, are only begin-
ning to be understood.
 Many allergic conditions are associated with dysbiosis; however, it remains unclear
whether it is the cause or an epiphenomenon of the disease.INTRODUCTION
Trillions of microorganisms thrive on and inside bodies and have done so, participating
in the shaping of physiology through millions of years of common evolution. The rela-
tionship between humans and their microbiota is truly mutualistic, with microorgan-
isms playing a significant role in host digestion, metabolism, and the immune
system. Several lines of evidence indicate that the human-associated microbes
have been selected based on coadaptation.1 Initially, microorganisms were regarded
as mere pathogens, which cause infections and disease and which the host immune
system should recognize and eliminate. It has become increasingly clear, however,
that microorganisms influence most aspects of human physiology, and, conversely,
the host immune system has largely developed to support the mutualistic relationship
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Fyhrquist378evidenced by a study comparing germ-free mice with conventionally raised mice,
revealing that most metabolites in host blood are derived from the gut microbiota.2
Therefore, significant perturbations in the microbial community, or dysbioses, may
have profound effects on the host, which may result in developing chronic inflamma-
tion and disease, especially in genetically predisposed individuals.
The composition of the human microbiota is largely determined by anatomic site,
with some interpersonal variation. Thus, individuals can be grouped according to
the occurrence of major phyla at specific body sites. Moreover, there is temporal vari-
ability in the composition, influenced by diet, season, or changes in the state of phys-
iology, including regularly occurring fluctuations, such as the menses, or isolated
phenomena, such as pregnancy.3,4 Nevertheless, themicrobiota of 1 individual usually
varies fairly narrowly, except when significantly perturbed by agents, such as anti-
biotic treatments or infections. Such episodes can lead to a new transient equilibrium
or even a new stable state. The concept of resilience, that is, the capacity of an
ecosystem to recover from perturbations, is central in the context of health and the hu-
man microbiota. Although adult microbiotas usually are highly resilient, children are
more vulnerable, and frequent perturbations may lead to increasingly impaired recov-
ery each time, with implications for health.
Chronic inflammatory diseases are on the rise worldwide today; the central role of
the immune system in driving disease is only beginning to be understood. Yet, how
the environment, including the humanmicrobiota, may trigger this development, is un-
known. For many conditions and illnesses, a challenge is to discover whether there is a
causal link between variations in the microbiota and pathology. It has been hypothe-
sized that although human ecology changes, so does the microbiota, with implications
for health. A modern lifestyle, including large-scale urban living, cesarean sections,
replacement of breast milk with formula, cleaner drinking water, smaller families,
and frequent antibiotics, has brought with it dramatic changes to the transmission
and maintenance of the indigenous microbiota, resulting in long-term effects on its
composition and stability. And if the microbiota affects physiology, and its composi-
tion has changed, it should be no surprise that this might alter host homeostasis
and, as a consequence, disease risk.5ALLERGIES AND IMMUNOREGULATION BY THE HUMAN RESIDENTIAL MICROBIOTA
Allergic diseases, including asthma, rhinitis, atopic dermatitis (AD), and food allergies,
have been increasing to epidemic proportions during the past century, especially in
high-income countries. The idea that there might be a link between the allergy
epidemic and reduced microbial exposure was first proposed in 1989. The so-
called hygiene hypothesis, formulated by Dr David Strachan,6 suggested that a lower
frequency of infections in early childhood could explain the rise in atopic diseases dur-
ing the twentieth century. Later on, the hygiene hypothesis was refined to include the
old friends hypothesis,7 which suggests that it is not the infections that protect against
allergies; rather, the allergy epidemic is a result of a loss of sufficient interaction with
health-promoting microbes—old friends—which have been present through thou-
sands of years of common evolution and the evolvement of the mammalian immune
system. Moreover, the hygiene hypothesis was expanded in 2010 by von Hertzen
and colleagues8 into the biodiversity hypothesis, which suggests that, in addition to
microbes in the home, in food, in drinking water, and on domestic animals, microbes
of the living environment, in general, may play a key role in shaping the composition of
microbial communities on the skin, in the respiratory system, and in the gut, with con-
sequences for physiology and health.
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because they performed crucial physiologic functions. Moreover, humans evolved to
tolerate other harmless organisms, which inevitably were taken daily into the body in
large quantities, and also organisms that induced low-level infections but were toler-
ated, such as helminths, Salmonella, hepatitis A virus, and Helicobacter. pylori. Some
of these organisms, such as blood nematodes, can be harmful, but, once established,
trying to eliminate them may cause pointless immunopathology. These microbes
continuously stimulate the immune system via microbe-associated molecular patterns
or pathogen-associated molecular patterns and cognate pattern recognition recep-
tors, and it is natural to conceive that the immune system evolved to detect and elim-
inate these potentially dangerous organisms. What is less obvious, however, is that
microbial exposures at the same time also serve to down-regulate the immune sys-
tem, preventing it from developing inappropriate inflammatory responses against
self, harmless allergens, and gut contents. These are all targets in autoimmune dis-
eases, allergic disorders, and inflammatory bowel diseases. Moreover, the regulatory
mechanisms should be able to shut down ongoing inflammatory responses and down-
regulate unnecessary background inflammation.9
The mechanisms via which the human residential microbiota may be regulating the
immune system are only beginning to be understood. These include secreted mole-
cules or metabolites, such as short-chain fatty acids (SCFAs), which can induce the
differentiation of regulatory dendritic cells (DCs) or the expansion of regulatory
T-cell (Treg) populations.10,11 Moreover, microbes can influence the immune system
through the induction of helper T cell type 1 (TH)-type immune responses, which inhibit
the development of TH2 cells and thereby protect against helper T cell type 2 (TH2)-
driven allergies. Endotoxins stimulate macrophages and antigen-presenting cells to
produce interleukin (IL)-12, which triggers the development of TH1 immunity.
Microbe-induced programming might further involve epigenetic modifications at
immune-related genes, including histone acetylation.12THE GUT MICROBIOTA AND THE DEVELOPMENT OF ATOPIC DISEASE
The largest collection of human bacteria, by far, is found in the distal gut, consisting of
500 to 1000 different species, including the phyla Bacteroidetes, Firmicutes, Actino-
bacteria, Proteobacteria, and Verrucomicrobia. The host immune system has evolved
to cope with the massive microbial presence by learning to judge correctly between
rejecting or accepting new species and to optimally control retained species. In
turn, the gut microbiota has developed strategies to both reinforce resistance against
harmful invaders and to avoid rejection by the host. These include boosting of host de-
fense as well as the induction of regulatory mechanisms, including the activation of
Tregs. Treg induction seems to be a widespread feature of microbiota colonization.13
The bacterium Bacteroides fragilis, for instance, is able to drive the differentiation of IL-
10–secreting Tregs, by producing an unusual capsular polysaccharide A,10 and mem-
bers of Clostridia metabolize SCFAs, which can have systemic antiinflammatory ef-
fects, through influencing DCs and T-cell responses. Segmented filamentous
bacteria (SFB) is an example of the opposite, an organism that is able to promote
effector responses through driving TH1 and TH17 immunity.
14 SFB has a specific
feature of adhering strongly to the epithelium of the ileum and Peyer patches,15 in
contrast to most other members of the microbiota, which remain entrapped in the
mucus and have little or no physical contact with host epithelium. This feature facili-
tates sampling and presentation of SFB antigens to T cells by DCs and likely explains
the unusual ability of SFB to influence host immunity. Although SFB-deficient mice
Fyhrquist380lack TH17-type responses and are susceptible to bacterial infections, it is evident that
SFB plays a key role in strengthening the gut barrier.
Several studies underline the importance of the composition of the gut microbiota in
early life for proper gut development, immune cell maturation, and resistance to path-
ogens.16 Moreover, early-life dysbiosis of the gut microbiota has been linked with an
increased risk of chronic inflammatory disorders, including allergies, later in life. The
mode of delivery is important, with babies born by cesarean section colonized by
more Staphylococcus, Corynebacterium, and Propionibacterium species and fewer
Bacteroidetes and Actinobacteria compared with vaginally delivered babies, who
are enriched for Clostridia.17 Cesarean birth is linked to predisposition toward asthma
during childhood,18 and studies show that children with an altered or less diverse gut
microbiome composition early in life are more likely to develop asthma.19–21 Moreover,
perturbations of the gut microbiome, such as colonization by Clostridium difficile at an
early age, is significantly associated with the development of wheeze, and recurrent
antibiotics, having an impact on on the diversity of the microbiota early in life,22 corre-
late with the development of asthma.23 In contrast, breastfeeding is inversely related
with the risk of developing of asthma,24 and exposure to environmental microbes or
farming environments has been associated with protection against asthma.25–27 It re-
mains to be seen, however, whether the latter also is linked to shifts in communities in
the intestines, and whether the gut microbiota can directly drive atopic disease or
confer protection against disease remains unclear.THE CUTANEOUS MICROBIOME AND ATOPIC ECZEMA
The skin is colonized by trillions of microorganisms at a density of 1 106microbes per
square millimeter. The composition of the skin microbiota is dependent on the physi-
ology of the site, with sebaceous sites dominated by lipophilic organisms, such asPro-
pionibacterium species, and humid environments inhabited mainly by Staphylococcus
and Corynebacterium species.28 Skin communities are stable over time, especially in
themore sheltered areas, despite external challenges, such as sudden changes in tem-
perature, windiness, humidity, clothing, sweating, or the use of skin products. Studies
have shown that this stability is dependent on the maintenance of species and strains
over time rather than on the acquisition of species from the environment.29 Compared
with the gut, the skin is a hostile environment to microbes—scarce in nutrients, high in
salt concentration and antimicrobial peptides, and endowed with a low pH.30 Never-
theless, a few phyla have adapted well to these conditions, including Actinobacteria,
Bacteroidetes, Firmicutes and Proteobacteria—which also are abundantly present in
the gut, but at different proportions compared with the skin.
Similar to the gut microbiota, the skin microbiota is essential in the protection
against invaders and in educating the skin immune system as well as in skin meta-
bolism and xenometabolism.31 Skin microbes contribute to the maintenance of a
physical and immune barrier of the host and are able to induce the production of anti-
microbial peptides and activate complement, and regulate the levels of IL-b produced
by keratinocytes and local antigen-presenting cells (APCs), which in turn control the
capacity of resident T cells to produce IL-17 and interferon-g.32 Thus, analogous to
the gut microbiota, skin microorganisms can act as adjuvants to the skin immune
system.
One of the functions of normal skin microbiota is to suppress the growth of the path-
ogen Staphylococcus aureus, utilizing several mechanisms. For instance, S epidermi-
dis can generate peptide antibiotics (lantibiotics) with bactericidal effects against S
aureus. Moreover, a lantibiotic produced by S hominis, can act synergistically with
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ulins, which specifically inhibit S aureus and act cooperatively with host antimicrobial
peptides. Moreover, Propionibacterium acnes may inhibit the growth of S aureus,
through the generation of fatty acids by fermenting glycerol in sebum, which lowers
the local pH in skin.33 These bacteria are common on healthy skin but typically lacking
in inflamed skin, especially in AD.
Whether the microbiota is able to induce antiinflammatory responses in the skin re-
mains unclear. Skin contains the highest frequencies of Tregs in the body, and a large
fraction of these can be found in the vicinity of hair follicles.34 In neonates, but not in
adults, the colonization by S epidermidis results in an influx of activated Tregs, and
blocking their entry prevents tolerance to commensals.35 Tregs play an important
role in calibrating the immune response to microorganisms, but, although the skin
microbiota continuously undergoes shifts defined by developmental stages and in
the context of disease and infections, it remains unknown how the responses to these
microbial fluctuations are controlled. There are some examples of skin commensals
that promote regulatory responses, including Vitreoscilla filiformis, originally found in
thermal spa water, which can promote the accumulation of Tregs in the skin and pro-
tect against AD.36 Moreover, S epidermidis is known to induce IL-10 production by DC
in vitro,37 and Acinetobacter lwoffii is able to promote both IL-10 production and TH1
responses in the skin, conferring systemic protection against allergic sensitization and
inflammation in a mouse model.38
AD is a chronic inflammatory skin disease, characterized by intense itch and recur-
rent, inflammatory eczematous lesions.39 AD is one of the most common chronic dis-
eases and affects up to one-fifth of the population in developed countries. Previously,
AD pathogenesis was believed to be mediated primarily by abnormalities of humoral
and T-cell–mediated immunity, but recently, the epidermis and its barrier functions
have been placed at the forefront of research and management efforts. The strongest
risk factor of AD is a positive family history for atopic diseases,40 and systematic gene
mapping studies have identified multiple risk loci for AD. For instance, mutations in the
filaggrin gene (FLG) gene, which is involved in the formation of the epidermal skin bar-
rier, have been identified as major predisposing factors for atopic eczema.41 The, to
date, approximately 30 identified susceptibility loci, however, explain less than 20%
of the estimated heritability. For instance, most patients with AD do not have any
FLG mutations, and up to 60% of FLG mutation carriers do not develop atopic dis-
ease. Many of the risk genes contribute to immune abnormalities, in particular innate
immune signaling and T-cell activation. Most of them also are linked, however, to other
inflammatory diseases, suggesting that atopy nonspecific processes are involved.
Instead, environmental factors, such as the living environment, lifestyle, and diet,
are believed to drive the inherited disease susceptibility predisposition into manifesta-
tion. Although the incidence of AD has increased by 2-fold to 3-fold during the past
decades in industrialized countries,42 it has been suggested that a westernized life-
style may influence the disease outcome. Few proposed environmental risks are sup-
ported, however, by strong epidemiologic data, and, in general, little is known about
how inherited and environmental factors interact and how this pertains to disease
pathophysiology, course, and outcomes.
The skin microbiota frequently is disrupted in AD, with the diversity of the microbiota
greatly reduced in favor of the genus Staphylococcus—S aureus, in particular. AD is a
chronic, relapsing condition, with shifts in the microbiota associated with disease
flares.43 S aureus is an established trigger to disease,44 but how the skin microbiota
modulates disease is poorly understood. Treatment with antibiotics often is success-
ful, with decreasing disease severity along with the reduction of S aureus
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to the intensity of the symptoms, including delta toxin, which stimulates mast cells,
and alpha toxin, which damages the skin barrier through destroying keratinocytes.
S aureus also is able to generate phenol-soluble modulins, which stimulate cytokine
release; proteases, which damage the epidermal barrier; and superantigens, which
give rise to specific IgE and exacerbate the inflammatory response through nonspe-
cific activation of T cells.46,47 Recent studies reveal specific differences between
staphylococcal strains in the capacity to elicit skin inflammation, and certain strains
are particularly able and better suited than others at colonizing the inflammatory
skin site in AD skin,48,49 which contributes to the complexity of AD.
It remains unknown which host or microbiome-derived mechanisms either promote
or inhibit the colonization of AD skin by S aureus and what the conditions are that
trigger changes to the skin microbiota at the beginning of an AD flare. S. aureus usually
dominates the bacterial skin community in AD, along with an extensive loss of other
potentially beneficial species of bacteria. These bacteria may contribute to a healthy
skin environment through the generation of short chain fatty acids, which may function
both as relevant natural moisturizing factors and through lowering the skin pH.33 More-
over, certain gram positive anaerobic cocci (GPACs), including Finegoldia, stimulate
rapid induction of antimicrobial peptides in human keratinocytes, constituting an
important signalling mechanism to the keratinocytes when the skin is injured.50 There-
fore, the complete or partial absence of these potentially beneficial microbes may
exacerbate a dry and alkaline skin surface environment, and may cause impaired
danger signalling in the skin, priming it for further pathogen growth and inflammation.THE RESPIRATORY MICROBIOME AND ASTHMA
Until recently, the lung has been considered a sterile organ lacking microbial inhabi-
tants. Now, however, it has become evident that the healthy respiratory mucosa is
colonized by a range of bacterial communities.51 The relative abundance and load
of these phyla differ significantly from that of other body compartments, with the lower
respiratory tract among the least populated surfaces of the human body, with an esti-
mated number of 10 to 100 bacteria per 1000 human cells. The 2 predominant phyla in
the airways are Firmicutes and Bacteroidetes, with Actinobacteria, Proteobacteria,
and Fusobacteria minor constituents of the local microbiota. Like elsewhere on
mucosal surfaces, a balance between immune tolerance and inflammation must be
maintained in the lung and is in part regulated by the cross-talk between immune cells
and the microbiome.52 Changes in the microbial composition may negatively influence
the immune homeostatic networks, which has been clearly demonstrated in germ-free
mice, which display impaired tolerance and increased susceptibility to inflammation or
infections.53 Likely there is substantial cross-talk between mucosal sites, in particular
the lung and the gut, because chronic lung disorders often exhibit intestinal disease
manifestation, and, conversely, respiratory infections often are accompanied by intes-
tinal indications.54
The composition of the airway microbiota develops extensively from the time point
of birth and is influenced by the environment. Although it is clear that the microbiome
significantly influences host immunematuration and activity, it remains unclear to what
extent patterns of airway microbial dysbiosis actually drives disease. Birth mode
(vaginal or cesarean section) greatly influences the development of the gut, skin,
and respiratory microbiota, with implications for health later on, and the exposure to
environments conferred with a high microbial burden and diversity have proved to in-
fluence the risk of developing atopic disease and asthma.26,55
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airway diseases. One study has shown that the susceptibility to house dust mite
(HDM)-induced lung inflammation in a mouse model is dependent on age and associ-
ated with the gradually increasing load of Bacteroidetes in the lung. The younger mice
that were exposed to HDM generated significantly more exaggerated TH2-type re-
sponses compared with older mice.56 The protective effect in the older mice was
associated with an increased number of bacteria in the airways and a shift from pre-
dominance of Gammaproteobacteria and Firmicutes to Bacteroidetes. Oral supple-
mentation of beneficial microbes, such as Bifidobacterium, or microbial metabolites,
such as SCFAs, similarly has provided protection against allergic sensitization and
inflammation, providing evidence that the gut and lung are closely linked in this
context. Several studies also have suggested that direct exposure of the respiratory
epithelium to microbial products provides some protective effects. For instance,
exposure to dust from farm environments protects mice against HDM-induced
asthma via A20-dependent mechanisms in the airway epithelium.55 Furthermore,
Stein and colleagues26 have shown that exposure of mice via the airways to dust
from Amish houses, but not Hutterite houses, protect against asthma in mice, via
MyD88-dependent and Trif-dependent mechanisms.
In humans, the risk of asthma is associated with lifestyle and microbial exposures,
and early-life dysbiosis of the gut microbiota has been consistently associated with
the increased risk of asthma later in life. Asthma recently has been shown to associate
also with a significant dysbiosis in the airway microbiota, including an increase in the
diversity the phylum Proteobacteria,57 with the appearance of families, such as Coma-
monadaceae, Sphingomonadaceae, and Pseudomonadaceae. These results are still
controversial, however, and further clinical trials and microbiome studies are needed.THE KARELIA STUDY
In the author’s study, focusing on children in Finnish and Russian Karelia, allergic
symptoms and atopic diseases are systematically more common in Finnish children
and adults compared with their Russian counterparts. These 2 adjacent areas are
geologically and climatically similar but socioeconomically highly distinct. In Russian
Karelia, hay fever is almost nonexistent, and only 2% of the children are sensitized
to birch pollen. In Finland, approximately one-sixth of the children suffer from hay fe-
ver, and 27% are sensitized to birch pollen.58 On the Finnish side, the author showed
that biodiversity of the living environment is related to the composition of the micro-
biota on the skin in these children and the risk of developing allergic disease. Further-
more, the author observed that the abundance on the skin of the phylum
Gammaproteobacteria down to the genus-level Acinetobacter in these children was
significantly associated with the capacity of the immune cells in peripheral blood to
produce antiinflammatory cytokine IL-10,25 feeding into a network of regulatory
gene expression. The author further examined the capacity of Acinetobacter to modify
immune responses in vitro and in vivo and found that compared with other human
commensals, including S epidermidis and E. coli, Acinetobacter species were partic-
ularly potent at inducing antiinflammatory and TH1-type immune responses in human
keratinocytes and human monocyte–derived DCs as well as locally in the skin in a
mouse model, protecting against systemic allergic sensitization and inflammation.38
Both the diversity and the abundance of Acinetobacter species on the skin and on
the nasal epithelium were significantly higher in Russian children compared with chil-
dren in Finnish Karelia, linking cutaneous Acinetobacter with the unusually low preva-
lence of allergic disease in the Russian area.59
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tuning of hostmicrobiomes and the immune system, the author exposedmice to soil for
2.5months, using siblings kept on clean bedding as controls. Exposure to soil modified
the gutmicrobiota of themice extensively, including a significant shift in its composition
including an increased abundance of Bacteroidetes relative to Firmicutes. A low ratio of
Bacteroidetes to Firmicutes in the gut microbiota previously was linked by several
studies to various inflammatory conditions, such as obesity60 and diabetes61 and the
development of asthma in human babies.62,63 Moreover, in the soil exposed mice,
the author observed significantly up-regulated expression of antiinflammatory signaling
in the intestinal epithelium of the ileum, which is the most distal part of the small intes-
tines. The ileum is an immunologically highly active tissue, containing numerous Peyer
patches, which are engaged in the surveillance of microorganisms in the intestinal
lumen and facilitate the generation of immune responses within the mucosa.64 When
exposing the mice to the experimental asthma protocol, the author observed that the
inflammatory response was significantly alleviated in the soil exposed mice.27 Thus,
the author’s work provides evidence of the role of environmentally acquired microbes
in modifying the gut microbiota, and alleviating TH2-driven allergic inflammation.
SUMMARY
The living environment has profound influence on human health, mediated in part by
modifications in the human microbiota. The human microbiota in turn influences
both the development and the calibration of the immune system, with consequences
for human health. The prevalence of allergies has reached epidemic levels during the
past 4 decades, especially in high-income countries, and there is evidence that this
phenomenonmight be linked to reduced exposures to beneficial environmental micro-
organisms, and allergic disease often is associated with perturbations in the human
microbiota. It remains unclear, however, if microbial dysbiosis actually can drive rele-
vant disease mechanisms or if it simply reflects associated phenomena, such as
altered patterns of immune responses to microbes and environmental stimuli.
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